Abstract: The metabolic disorder affects about 30% of the US population with escalating prevalence. In this study, the relationships between the metabolic disorder and the occurrence and rigorousness of cardiovascular disease in common and coronary artery disease in particular were explored. The impression of metabolic disorder on outcomes of coronary revascularization therapies and coronary collateral development was specifically compiled. Besides, the association between the metabolic disorder and its individual component pathologies and oxidative stress were also examined. Researchers discuss the apparent lack of encouraging influence of antioxidants on cardiovascular consequences in enormous clinical trials with stress on some of the restrictions of these trials. Lastly, researchers highlight verification for booming application of antioxidant assets of pharmacological agents, including metformin, statins, angiotensin II type I receptor blockers and angiotensin II converting enzyme inhibitors for preclusion and management of the cardiovascular impediments of the metabolic disorder.